Skip to content
Open Access
  • Home
  • Collections
    • High Impact Articles
    • Jawi Collection
    • Malay Medicine
    • Forensic
  • Search Options
    • UiTM Open Access
    • Search by UiTM Scopus
    • Advanced Search
    • Search by Category
  • Discovery Service
    • Sources
    • UiTM Journals
    • List UiTM Journal in IR
    • Statistic
  • About
    • Open Access
    • Creative Commons Licenses
    • COKI | Malaysia Open Access
    • User Guide
    • Contact Us
    • Search Tips
    • FAQs
Advanced
  • Search
  • Correction: harnessing soluble...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Correction: harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy.

Correction: harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy.

Show other versions (2)
Bibliographic Details
Main Authors: Tal I Arnon, Gal Markel, Ahuva Bar-Ilan, Jacob Hanna, Eyal Fima, Fabrice Benchetrit, Ruth Galili, Adelheid Cerwenka, Daniel Benharroch, Netta Sion-Vardy, Angel Porgador, Ofer Mandelboim
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4418968?pdf=render
  • Holdings
  • Description
  • Other Versions (2)
  • Similar Items
  • Staff View

Internet

http://europepmc.org/articles/PMC4418968?pdf=render

Similar Items

  • Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy.
    by: Tal I Arnon, et al.
    Published: (2008-01-01)
  • Correction: Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy
    by: Tal I. Arnon, et al.
    Published: (2008-01-01)
  • Correction: Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy.
    by: Tal I. Arnon, et al.
    Published: (2008-01-01)
  • CD100 on NK cells enhance IFNgamma secretion and killing of target cells expressing CD72.
    by: Sa'ar Mizrahi, et al.
    Published: (2007-09-01)
  • Targeting natural killer cell reactivity by employing antibody to NKp46: implications for type 1 diabetes.
    by: Rami Yossef, et al.
    Published: (2015-01-01)

© 2020 | Services hosted by the Perpustakaan Tun Abdul Razak, | Universiti Teknologi MARA | Disclaimer


Loading...